Key takeaways:
- Aflibercept 8 mg achieved sustained enhancements in visible acuity and central retinal thickness.
- Some sufferers achieved prolonged dosing intervals past 16 weeks and 20 weeks.
FORT LAUDERDALE, Fla. — Aflibercept 8 mg demonstrated sustained practical and anatomic enhancements in sufferers with moist age-related macular degeneration by means of 156 weeks, based on a presenter.
On the Retina World Congress, David T. Wong, MD, FRCSC, DRCPSC, introduced outcomes from the PULSAR extension research, which builds on the preliminary PULSAR research investigating aflibercept 2 mg dosed each 8 weeks (336 sufferers), aflibercept 8 mg dosed each 12 weeks (335 sufferers) and aflibercept 8 mg dosed each 16 weeks (338 sufferers), all after three preliminary month-to-month injections. At 96 weeks as a part of the extension research, 208 sufferers switched from aflibercept 2 mg to aflibercept 8 mg each 12 weeks, and 417 sufferers continued their earlier aflibercept 8 mg dosing routine.
Anthony DeFino
“These findings are suggesting that sufferers with treatment-naive neovascular AMD can obtain a sturdy enchancment with aflibercept 8 mg over this time interval,” Wong mentioned.
Based on Wong, the imply finest corrected visible acuity at 96 weeks was 66.9 letters, a “substantial enchancment” from baseline, and the extension research confirmed a lack of lower than three letters. The typical variety of complete injections by means of week 156 was 17.5 amongst sufferers who switched from aflibercept 2 mg to aflibercept 8 mg and 12.7 amongst sufferers who obtained aflibercept 8 mg.
Central retinal thickness improved all through the research period, beginning at 418 µm at baseline on common and lowering to 274 µm amongst these within the aflibercept 8 mg group and 275 µm amongst those that switched from aflibercept 2 mg.
Based on Wong, 40% of sufferers within the aflibercept 8 mg group achieved prolonged dosing intervals past 20 weeks, and 42% of those that switched to aflibercept 8 mg achieved dosing intervals past 16 weeks.
“Ocular and non-ocular security is kind of related between each teams,” Wong mentioned. “There have been no security alerts.”
Sources/Disclosures
Collapse
Wong DT, et al. PULSAR extension: Medical enhancements sustained over 156 weeks with aflibercept 8 mg in sufferers with neovascular age-related macular degeneration. Introduced at: Retina World Congress; Could 8-11, 2025; Fort Lauderdale, Florida.
Disclosures:
Wong experiences receiving analysis grants from AbbVie, Alcon, Apellis, ArcticDx, Bausch Well being, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon, Zeiss and 20/20 Innovation Hub. Please see the research for all different authors’ related monetary disclosures.
